Advanced Search
Contact | Corporate | Help

Erlotinib Plus Chemotherapy for Treatment of Triple Negative Breast Cancer

Sponsors:
  • University of Kansas
  • Genentech
Phases:
  • Phase II
IndicationsAcronym:
  • Breast Cancer
Age Groups:
  • Adult
  • Senior
Gender:
Female
Names:
  • Drug: Erlotinib
Enrollment:
30

Additional information about NCT00491816.


SourceSolution © 2008-2012